Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 67.6% in February

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 21,126 shares, a drop of 67.6% from the January 29th total of 65,207 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 155,980 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 155,980 shares, the short-interest ratio is currently 0.1 days. Approximately 0.9% of the shares of the company are short sold.

Virax Biolabs Group Trading Up 13.2%

Shares of Virax Biolabs Group stock opened at $0.24 on Thursday. Virax Biolabs Group has a 1 year low of $0.20 and a 1 year high of $1.85. The company has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $0.48.

Virax Biolabs Group (NASDAQ:VRAX) last posted its quarterly earnings data on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The firm had revenue of $0.00 million for the quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $1.00 target price (down from $3.00) on shares of Virax Biolabs Group in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Friday, January 9th. Finally, Zacks Research upgraded Virax Biolabs Group to a “hold” rating in a research note on Tuesday, January 13th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Virax Biolabs Group has an average rating of “Hold” and a consensus target price of $1.00.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.